MetaCap

Humacyte Inc. (HUMA)

NASDAQ: HUMAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.4454-0.0971 (-17.90%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

HUMA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$123.73M
EPS (TTM)
-$0.45
52-week range
0.337 – 1.53
Day range
0.4444 – 0.52
Volume / Avg
5.77M / 5.36M
Beta
—

52-week range

$0.337$1.53

HUMA stock today

Humacyte (HUMA) closed at $0.4454 on Nov 20, down 17.90% (-$0.0971), versus the S&P 500's 3.70% decline. Shares are 70.8% below their 52-week high of $1.53, set on Jun 4, 2026 and 32.2% above the 52-week low of $0.337, near the bottom of the past year's range. HUMA is down 53.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 63.5%.

Humacyte has posted a net loss over the last twelve months (EPS of -$0.45), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Humacyte

Company profile

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Laura E. Niklason M.D., Ph.D.
Headquarters
Durham, NC
Employees
184
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Humacyte generated $2.0 million in revenue, up 0.0% from fiscal 2024. Humacyte reported a net loss of $40.8 million, compared with a loss of $148.7 million a year earlier. Gross margin was -376.1% and operating margin -5306.0%.

Humacyte annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$2.04M$0———
Growth—————
Net income$-40.83M$-148.70M$-110.78M$-11.96M$-26.48M
EPS (diluted)$-0.26$-1.26$-1.07$-0.12$-0.66

Analyst forecast

Forecast

Consensus (6 analysts)

buy

Avg. price target

$1.64+268.21%

  • Strong buy 1
  • Buy 3
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $0.60High $4.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.06 vs $-0.09
Surprise
+33.33%

HUMA news

All HUMA news

Humacyte peers

Health Care sector
HUMA peer companies
CompanyPrice% ChgMarket capCompare
CMPXCompass Therapeutics Inc.0.6882+1.43%$123.94Mvs HUMA
IVVDInvivyd Inc.0.4127-7.45%$122.01Mvs HUMA
ENGNenGene Therapeutics Inc.1.74-1.14%$116.61Mvs HUMA
ARMPArmata Pharmaceuticals Inc.3.03+1.68%$112.69Mvs HUMA
FATEFate Therapeutics Inc.0.919-9.01%$111.82Mvs HUMA
CRDLCardiol Therapeutics Inc. Class A0.8626-2.28%$110.14Mvs HUMA
TARAProtara Therapeutics Inc.2.28-5.00%$140.38Mvs HUMA
STROSutro Biopharma Inc.8.60-1.38%$142.77Mvs HUMA

Indexes, lists and sector

Humacyte stock FAQ

What is Humacyte's stock price today?

HUMA last traded at $0.4454 as of Nov 20, 4:00 PM EST, down 17.90% on the day. Prices are delayed at least 15 minutes.

Who is Humacyte's CEO?

Dr. Laura E. Niklason M.D., Ph.D. is the chief executive officer of Humacyte Inc., which has about 184 employees.

What is the HUMA 52-week high?

The 52-week high for HUMA is $1.53 and the 52-week low is $0.337. The stock is currently 70.8% below its high.

Compare HUMA